Cornerstone Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial of CPI-613 in Patients With Locally Advanced or Metastatic Pancreatic Cancer

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CRANBURY, N.J., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase II clinical trial of CPI-613 for the treatment of patients with locally advanced or metastatic pancreatic cancer. CPI-613 is the Company’s lead Altered Energy Metabolism Directed (AEMD) drug candidate, which is designed to disrupt the altered energy-production pathways in cancer cells.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC